Literature DB >> 11146272

The validity of medicaid pharmacy claims for estimating drug use among elderly nursing home residents: The Oregon experience.

D A McKenzie1, J Semradek, B H McFarland, J P Mullooly, L E McCamant.   

Abstract

This study compared computerized Medicaid pharmacy claims data for nursing home residents with chart data to establish how well the claims data identified those receiving drugs within three different psychoactive drug classes (yes/no for each class) and how well the claims estimated total within-class average daily dose. Percent agreement, positive predictive value (PPV), and negative predictive value (NPV) for drug exposure were over 85% for each class. Kappas were excellent for antipsychotics and antidepressants, and good for anxiolytics. Correspondence was lower for average daily dose. Using an algorithm that credits some but not all doses associated with overlapping claims, correlations ranged from 0.97 to 0.66. Agreement on therapeutic dose was excellent for antipsychotics (kappa = 0.81) and fair to good for antidepressants and anxiolytics (kappa = 0.63, and kappa = 0.52, respectively). The findings suggest that Medicaid pharmacy claims data are reasonably accurate for quality assurance and accreditation purposes.

Mesh:

Year:  2000        PMID: 11146272     DOI: 10.1016/s0895-4356(00)00259-6

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


  18 in total

1.  Early discontinuation of treatment in patients with orthostatic hypotension.

Authors:  C Shibao; C G Grijalva; L A Lipsitz; I Biaggioni; M R Griffin
Journal:  Auton Neurosci       Date:  2013-08-20       Impact factor: 3.145

2.  Risk of Suicidal Events With Atomoxetine Compared to Stimulant Treatment: A Cohort Study.

Authors:  Stephan Linden; Regina Bussing; Paul Kubilis; Tobias Gerhard; Richard Segal; Jonathan J Shuster; Almut G Winterstein
Journal:  Pediatrics       Date:  2016-05       Impact factor: 7.124

Review 3.  Observational studies of the association between glucose-lowering medications and cardiovascular outcomes: addressing methodological limitations.

Authors:  Elisabetta Patorno; Amanda R Patrick; Elizabeth M Garry; Sebastian Schneeweiss; Victoria G Gillet; Dorothee B Bartels; Elvira Masso-Gonzalez; John D Seeger
Journal:  Diabetologia       Date:  2014-09-12       Impact factor: 10.122

4.  Validity of the Finnish Prescription Register for measuring psychotropic drug exposures among elderly finns: a population-based intervention study.

Authors:  Maria Rikala; Sirpa Hartikainen; Raimo Sulkava; Maarit Jaana Korhonen
Journal:  Drugs Aging       Date:  2010-04-01       Impact factor: 3.923

5.  Increasing incidence of new-onset diabetes after transplant among pediatric renal transplant patients.

Authors:  Thomas E Burroughs; Jason P Swindle; Paolo R Salvalaggio; Krista L Lentine; Steven K Takemoto; Suphamai Bunnapradist; Daniel C Brennan; Mark A Schnitzler
Journal:  Transplantation       Date:  2009-08-15       Impact factor: 4.939

6.  National trends in antidepressant medication treatment among publicly insured pregnant women.

Authors:  Krista F Huybrechts; Kristin Palmsten; Helen Mogun; Mary Kowal; Jerry Avorn; Soko Setoguchi-Iwata; Sonia Hernández-Díaz
Journal:  Gen Hosp Psychiatry       Date:  2013-01-30       Impact factor: 3.238

7.  Reliability of medicaid claims versus medical record data: in a cost analysis of palivizumab.

Authors:  Julie Jacobson Vann; John Feaganes; Steven Wegner
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

8.  Incidence of health insurance claims for thyroid neoplasm and pancreatic malignancy in association with exenatide: signal refinement using active safety surveillance.

Authors:  David D Dore; John D Seeger; K Arnold Chan
Journal:  Ther Adv Drug Saf       Date:  2012-08

9.  Outpatient antipsychotic treatment and inpatient costs of schizophrenia.

Authors:  Steven C Marcus; Mark Olfson
Journal:  Schizophr Bull       Date:  2007-06-19       Impact factor: 9.306

10.  Treatment of schizophrenia with long-acting fluphenazine, haloperidol, or risperidone.

Authors:  Mark Olfson; Steven C Marcus; Haya Ascher-Svanum
Journal:  Schizophr Bull       Date:  2007-04-29       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.